Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesalazine + lactobacillus casei
- Development stage
- Unknown
- Lead developer
- Tillotts Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Mesalazine + lactobacillus casei is a combination therapy consisting of mesalazine (also known as mesalamine), an anti-inflammatory aminosalicylate drug, and Lactobacillus casei, a probiotic bacterium. Mesalazine acts primarily by inhibiting cyclooxygenase and lipoxygenase pathways, reducing the synthesis of pro-inflammatory mediators such as prostaglandins and leukotrienes in the intestinal mucosa. Lactobacillus casei is a beneficial microorganism that modulates gut microbiota composition and exerts anti-inflammatory effects through immune modulation and competitive inhibition of pathogenic bacteria. This combination has been studied for maintaining remission in symptomatic uncomplicated diverticular disease (SUDD) of the colon and for its potential benefits in ulcerative colitis by reducing inflammatory cytokines, myeloperoxidase activity, nitric oxide levels, and expression of iNOS/COX-2 genes[1][2][3][8][10]. The synergistic effect appears to enhance clinical outcomes compared to either agent alone.
02
Targets
15-LOX (Lysyl Oxidase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on mesalazine + lactobacillus casei.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesalazine + lactobacillus casei.